Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data

Valneva SE (NASDAQ:VALN) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In.

On March 23, 2026, Jefferies reiterated a Buy rating and $15 price target on Valneva SE (NASDAQ:VALN) following topline results from the Phase 3 VALOR trial of its Lyme disease vaccine candidate PF-07307405. Jefferies said that the stock reaction reflects a headline miss on statistical significance, noting 73.2% efficacy at 28 days post-dose did not meet the required threshold on the lower bound of the confidence interval. The firm has added that the weakness presents a buying opportunity on the shares of Valneva SE (NASDAQ:VALN) with a path to approval still intact.

On the same day, Pfizer and Valneva SE (NASDAQ:VALN) have announced the topline results from the Phase 3 VALOR trial showing 73.2% efficacy from 28 days post-dose and 74.8% efficacy from one day post-dose in reducing confirmed Lyme disease cases versus placebo. Pfizer and Valneva SE (NASDAQ:VALN) have said that fewer cases than expected were recorded, and the first pre-specified statistical criterion was not met, but noted the second analysis showed a confidence interval lower bound above 20, supporting plans for regulatory submissions.

Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data

Pixabay/Public Domain

Valneva SE (NASDAQ:VALN) develops, manufactures, and commercializes vaccines for infectious diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.